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The patient was a 54-year-old woman who developed a
right adrenal tumour, Cushingoid features, elevated
levels of cortisol that were not suppressed by 1 nor
8mg of dexamethasone, and suppression of adrenocorti-
cotropin (ACTH) during treatment for severe hypertension.
Computed tomography (CT) revealed a right adrenal
tumour and an atrophic left adrenal gland. In addition,
elevated plasma aldosterone concentration (PAC) and
suppressed plasma renin activity (PRA) with an aldoster-
one-to-renin ratio of 128 (ng per 100ml per ngml
–1h
 1)
suggested aldosterone excess. Urinary excretion of
aldosterone was relatively high, and the captopril and
rapid ACTH tests resulted in no response of PRA and
exaggerated increase in PAC, respectively. ACTH-loaded
adrenal venous sampling showed bilateral excess of
aldosterone with right predominance of cortisol. Right
laparoscopic partial adrenalectomy (ADX) and immuno-
histochemical analysis showed both a cortisol-producing
adenoma and an aldosterone-producing microadenoma
(microAPA) within the attached adrenal, which had not
been detected by CT preoperatively. After the right partial
ADX, her blood pressure, aldosterone level and sup-
pressed PRA remained unchanged. Subsequently, laparo-
scopic total left ADX was performed. Two microAPAs
with paradoxical hyperplasia were revealed within the
apparently atrophic left adrenal gland. Soon after the
second surgery, her blood pressure normalized without
requiring any anti-hypertensive medication.
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Introduction
Aldosterone, in concert with a high salt intake, has a
pivotal role in the pathophysiology of hypertension
and causes potentially serious damage to the
cardiovascular, cerebrovascular and renal systems,
resulting in atherosclerotic and/or fibrotic remodel-
ing through activation of mineralocorticoid recep-
tors
1 or other mechanisms not yet elucidated.
Primary aldosteronism has been attracting more
and more attention from clinical and basic scien-
tists, because its prevalence in referral centres has
been reported to be more than 10% among hyper-
tensive patients,
2 making it a common disease rather
than an unusual endocrine disorder. Cortisol has
been widely studied as a possible culprit of meta-
bolic syndrome. Excess secretion of both aldoster-
one and cortisol, therefore, might result in severe
hypertension and comorbidities.
We describe the case of a patient in whom
hypersecretion of aldosterone and cortisol resulted
in difficult-to-control hypertension. The patient was
diagnosed as having adrenocorticotropic hormone
(ACTH)-independent Cushing syndrome with con-
comitant hypersecretion of aldosterone. Lateralization
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www.nature.com/jhhof aldosterone hypersecretion was determined by
bolus cosyntropin-stimulated adrenal venous sam-
pling (AVS). On the basis of the results obtained by
AVS, two-stage surgery, that is, right partial adrena-
lectomy (ADX) and subsequent total left ADX, was
performed to stop excessive secretion of both
hormones. After the surgery, severe hypertension
resolved, and eventually this case presented an
unreported condition of bilateral aldosterone-produ-
cing microadenomas (microAPAs) associated with a
cortisol-producing adrenal macroadenoma.
Case report
A 54-year-old woman was referred to our hospital
for evaluation of hypertension and a right adrenal
tumour. She had been diagnosed as having hyper-
tension and had started taking anti-hypertensive
medication at the age of 42. A few months before her
referral to our hospital, abdominal ultrasonography
for a routine check-up revealed that she had a right
adrenal tumour, and she was admitted for further
evaluation.
On admission she showed central obesity, BMI of
27kgm
–2 and a moon face. Her blood pressure was
152/106mmHg with a pulse rate of 65 beats per
minute although she was on nifedipine 40mgday
–1,
bunazosin 6mgday
–1 and carvedilol 10mgday
–1.O n
physical examination, she showed pretibial oedema
and multiple ecchymoses on her lower extremities.
Before the evaluation of the adrenal tumour and
hypertension, carvedilol was discontinued, and
both benidipine and doxazosin were added to
control her blood pressure. We intentionally limited
the use of anti-hypertensive agents to calcium-
channel blockers and alpha1-blockers to minimize
effects on renin–angiotensin–aldosterone system by
other medications during a diagnostic process.
2
Complete blood cell count and electrolyte analysis
showed a mildly elevated neutrophil count of 76%,
a decreased eosinophil count of 1% without leuko-
cytosis and normokalemia of 4.1mmoll
–1 (Table 1).
Repeated 24-h urinary collections showed an aver-
age creatinine clearance of 78mlmin
–1 with micro-
albuminuria of 61mgday
–1. The endocrinological
examination (Table 1) revealed that the circadian
rhythm of the hypothalamo–pituitary–adrenal axis
was disturbed with both persistently suppressed
ACTH levels (assay sensitivity: 5pgml
–1) and ele-
vated cortisol levels ranging from 17.1 to 24.0mg per
100ml. The levels of urinary free cortisol were also
Table 1 Electrolytes and endocrinological findings
Before right partial ADX After right partial ADX
Electrolytes
Serum Na (mmoll
–1) 145 145
Serum K (mmoll
–1) 4.1 4.2
Urinary Na (mmoll
–1)6 8 7 5
Urinary K (mmoll
–1)2 1 2 5
HPAA and RAAS circadian rhythm 0500h 1100h 1700h 2300h 0500h 1100h 1700h 2300h
ACTH (pgml
–1) N D N D N D N D N DN DN D N D
Cortisol (mg per 100ml) 24.0 18.9 18.1 17.1 ND ND ND ND
PRA (ngml
–1 per hour) 0.1 0.3 0.3 0.2 0.1 0.2 0.4 0.3
Aldosterone (ng per 100ml) 12.8 19.6 15.9 9.7 8.1 14.7 8.0 15.0
ARR (ng per 100ml per ngml
–1 per hour) 128.0 65.3 53.0 48.5 81.0 73.5 20.0 50.0
Urinary steroids
a
Urinary free cortisol (mgday
–1) 672.0 (448–690) ND
Urinary aldosterone (mgday
–1) 9.4 (8.2–10.7) 8.9 (8.2–9.7)
Overnight DST 1mg 8mg
ACTH (pgml
–1)N D N D
Cortisol (mg per 100ml) 17.4 14.7
Rapid ACTH test, 250mg (min) 0 15 30 60 90 0 15 30 60 90
Aldosterone (ng per 100ml) 9.3 NA 60.0 67.1 58.9 8.6 37.8 45.5 50.4 54.4
Cortisol (mg per 100ml) 18.5 NA 32.2 33.8 34.1 ND 0.8 1.3 1.4 1.0
PRA (ngml
–1 per hour) 0.7 0.3
Captopril test, 50mg (min) 06 0 0 6 0
PRA (ngml
–1 per hour) 0.2 0.5 0.4 0.5
Aldosterone (ng per 100ml) 13.6 10.4 16.8 9.8
ARR (ng per 100ml per ngml
–1 per hour) 68.0 20.8 42.0 19.6
Abbreviations: ACTH, adrenocorticotropic hormone; ADX, adrenalectomy; ARR, aldosterone-over-renin ratio; DST, dexamethasone suppression
test; HPAA, hypothalamo-pituitary-adrenal axis; NA, not available; ND, not detected because of a value below assay sensitivity; PRA, plasma
renin activity; RAAS, renin–angiotensin–aldosterone system.
aData are medians (range) obtained from repeated collections.
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tests with 1 and 8mg resulted in cortisol levels of
17.4 and 14.7mg per 100ml, respectively. These
results were consistent with autonomous secretion
of cortisol, and she was diagnosed as having
Cushing syndrome. Adrenal computed tomography
(CT) with contrast medium showed a right adrenal
tumour of 30mm in diameter (Figure 1a), while the
left adrenal gland was found to be atrophic
(Figure 1b). Furthermore, elevated plasma aldoster-
one concentration (PAC) of 12.8ng per 100ml and
suppressed plasma renin activity (PRA) of 0.1ng
ml
–1h
 1, which gave an aldosterone-to-renin ratio
(ARR) of 128, prompted us to confirm concomitant
aldosterone excess.
The circadian study showed elevated PAC (over
12ng per 100ml) except for the one obtained at 2300
hours along with persistently suppressed PRA
(o1ngml
–1h
 1) throughout the day, and the capto-
pril test resulted in no significant increase in PRA
with the ARR being 20.8 at 60min (Table 1). In
addition, a rapid ACTH test with 0.25mg cosyn-
tropin elicited a marked increase of aldosterone to
67.1ng per 100ml. AVS was performed, as reported
previously,
3 to determine the laterality of excessive
secretion of aldosterone and cortisol. Cortisol levels
from the right adrenal vein obtained before and after
cosyntropin stimulation were 146 and 1269mg per
100ml, respectively, and 6.3- and 8.8-fold higher
than those from the left adrenal vein, respectively,
confirming that the source of cortisol excess was the
right adrenal side (Table 2). Aldosterone levels
obtained from the right and left adrenal veins were
198 and 211ng per 100ml respectively at baseline,
and 2545 and 7134ng per 100ml respectively, after
an iv bolus injection of 0.25mg cosyntropin
(Table 2). On the basis of these results, we judged
that the patient presented hypersecretion of aldos-
terone from bilateral adrenals with left predomi-
nance.
3–5 Bilateral excess of aldosterone shown in
AVS raised some possibilities; (1) bilateral adrenal
hyperplasia, that is, idiopathic hyperaldosteronism;
(2) the CT-detectable right adrenal produced
both cortisol and aldosterone in addition to the
CT-undetectable microAPA within the left adrenal
gland; and (3) microAPAs were present in bilateral
adrenal glands. As it was not possible to differenti-
ate between tumour and hyperplasia except by
histopathological examination, we performed laparo-
scopic partial ADX of the right adrenal tumour to
spare as much of the apparently atrophic but non-
tumourous attached adrenal gland as possible, leav-
ing the possibility that the left adrenal gland might be
resected if excessive secretion of aldosterone and
difficult-to-control hypertension persisted.
Histopathological examination revealed that the
right adrenal tumour was 25mm in diameter, and
hematoxylin-eosin (HE) staining showed that it was
composed of compact and clear cells with predomi-
nance of the compact ones, fulfilling two out of
nine Weiss criteria,
6,7 that is, eosinophilic cytoplasm
and nuclear atypia, with focal lipoid degeneration
(Figure 2a). Immunohistochemistry of the right
tumour showed immunoreactivity to 3 beta-hydro-
xysteroid dehydrogenase (3b-HSD) and 17a-hydro-
xylase (P450c17) in the cytoplasm (Figures 2d and g,
respectively). In grossly atrophic, non-neoplastic
tissue of the right adrenal attached to the right
tumour, there was a micronodule of 2.1mm in
diameter (Figure 2b, HE staining). Homogenously
increased immunoreactivity to 3b-HSD (Figure 2e)
with diffusely attenuated immunoreactivity to
P450c17 (Figure 2h) coincided with the microno-
dule, indicating this was a microAPA.
8 The rest of
the attached non-neoplastic tissue of the right
adrenal showed atrophy of the zona fasciculata
and reticularis (Figure 2c, HE staining), and de-
creased immunoreactivity to 3b-HSD (Figure 2f) and
P450c17 (Figure 2i), consistent with ACTH-inde-
pendent Cushing syndrome. The zona glomerulosa,
in particular, of the right attached non-neoplastic
adrenal showed hyperplastic changes with focally
attenuated immunoreactivity to 3b-HSD (Figure 2f),
suggesting the ‘paradoxical hyperplasia’ observed
in patients with aldosterone-producing adenomas
(APA).
8
Immediately after the right partial ADX, the
patient started to receive glucocorticoid replacement
Figure 1 Adrenal CT showed (a) the right adrenal adenoma (arrow) and (b) the left atrophic adrenal gland without nodular lesions
(arrowhead).
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creased to undetectable using an assay with a
sensitivity of 0.8mg per 100ml. Her signs of Cushing
syndrome including moon face and central obesity
as well as pretibial oedema disappeared. The
aldosterone level remained, however, almost un-
changed. Subsequently, her blood pressure began to
rise after the partial ADX, resulting in the addition
of azelnidipine 16mgday
–1 to the preoperative
regimen. Eight months after the right partial ADX,
a second endocrinological examination was per-
formed (Table 1, right column). Circadian examina-
tion of the renin–angiotensin–aldosterone system
showed PAC ranging from 8.0 to 15.0ng per 100ml
with persistently suppressed PRA of o1ngml
–1h
 1
throughout the day, while the endogenous ACTH
was still undetected after the cure of Cushing
syndrome. Repeated measurement of urinary ster-
oids confirmed elevated aldosterone excretion with
the highest level being 9.7mgday
–1 and the median
8.9mgday
–1. Both post-captopril ARR of 19.6 at
60min and the exaggerated aldosterone response
(up to 54.4ng per 100ml) in the rapid ACTH test
suggested persistence of aldosterone excess. On the
basis of the histological proof of a microAPA in the
resected right adrenal tissue and the results of AVS,
we strongly suspected that the origin of aldosterone
excess might lie in the left adrenal gland. We then
performed laparoscopic total left ADX, based on the
endocrinological assessment and the patient’s strong
wish to control her hypertension requiring multiple
anti-hypertensive agents of nifedipine 40mgday
–1,
Table 2 Results of AVS
Cortisol (mg per 100ml) Aldosterone (ng per 100ml)
RAV LAV EIV RAV LAV EIV
Baseline 146 23.1 14.9 198 211 5.9
After ACTH 250mg 1269 144 26.1 2545 7134 33.0
Abbreviations: ACTH, adrenocorticotropic hormone; AVS, adrenal venous sampling; EIV, external iliac vein; LAV, left adrenal vein; RAV, right
adrenal vein.
Figure 2 Histopathology of the right adrenal tumour and the attached non-neoplastic adrenal tissue. (a, d, g) The right adrenal tumour,
(b, e, h) the aldosterone-producing microAPA (indicated by arrowhead) and (c, f, i) the attached non-neoplastic adrenal tissue, analyzed
by HE staining and immunohistochemistry of 3b-HSD and P450c17, respectively.
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–1, azelnidipine 16mgday
–1,
doxazosin 4mgday
–1 and bunazosin 6mgday
–1.
Immediately after the second ADX, her blood
pressure returned to normal without requiring any
anti-hypertensives, and PAC went down to 2.8ng
per 100ml with a PRA of 0.3ngml
–1h
 1; besides,
urinary excretion of aldosterone decreased to un-
detectable by postoperative day 7. Within the left
adrenal gland, HE staining showed two microno-
dules, one of 1.6mm (Figure 3a) and the other of
1.9mm (Figure 3b) in diameter, both of which
showed increased homogenous immunoreactivity
to 3b-HSD (Figures 3d and e, respectively), but not
to P450c17 (Figures 3g and 3h, respectively). More-
over, except for these two micronodules, the left
attached non-neoplastic adrenal showed hyperpla-
sia of the zona glomerulosa (Figure 3c), which was
diffusely negative for immunoreactivity to 3b-HSD
(Figure 3f), indicating ‘paradoxical hyperplasia’.
8
Finally, the patient was diagnosed as having a
cortisol-producing adrenocortical adenoma and a
microAPA in the right adrenal gland and two
microAPAs in the left adrenal gland. She remained
normotensive without any anti-hypertensive medi-
cation and fit with appropriate glucocorticoid
replacement, and a rapid cosyntropin stimulation
test performed 18 months after the second ADX
showed no response of cortisol from baseline of
Figure 3 Histopathology of the left adrenal gland. (a, d, g) One aldosterone-producing microAPA (indicated by arrowhead), (b, e, h)
another aldosterone-producing microAPA (indicated by arrowhead) and (c, f, i) the attached non-neoplastic adrenal tissue, analyzed by
HE staining and immunohistochemistry of 3b-HSD and P450c17, respectively. (f) The hyperplastic zona glomerulosa showing negative
immunoreactivity to 3b-HSD (arrowheads) showed paradoxical hyperplasia in the attached non-neoplastic adrenal tissue.
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aldosterone from 4.2 to 12.8ng per 100ml, as
compared with the peak level of 54.4ng per 100ml
before the second ADX.
Discussion
We have described the successful treatment of
a patient with severe endocrine hypertension
attributed to hypersecretion of cortisol and aldoster-
one because of unilateral, CT-detectable macroade-
noma and bilateral, CT-undetectable microAPAs.
Although several cases of simultaneous hypersecre-
tion of cortisol and aldosterone have been reported,
most of them were classified into two groups: one
because of a single, sometimes multiple, adrenocor-
tical macroadenoma(s) that produced both cortisol
and aldosterone,
9–14 and the other because of a
combination of cortisol-producing macroadeno-
ma(s) and aldosterone-producing macroadeno-
ma(s).
15–18 Furthermore, the preoperative diagnosis
of most of these cases were made on radiological
findings obtained by conventional CT as well as on
endocrinological findings.
9,11,12,15,16 In this case, we
preoperatively suspected the hypersecretion of
aldosterone from bilateral adrenals from the results
of AVS, and confirmed bilateral microAPAs as the
cause of aldosterone excess by immunohistochemi-
cal analysis of steroidogenic enzymes.
According to the Endocrine Society Guidelines for
management of primary aldosteronism,
2 a stepwise
approach is recommended to evaluate hypersecre-
tion of aldosterone: screening, confirmation tests
and subtype classification. We considered that the
diagnostic workup of aldosterone excess required
careful interpretation of endocrinological findings,
especially in the situation that the secretion of
endogenous ACTH was suppressed as in the present
case, because previous studies had found that
aldosterone secretion in patients with an APA was
regulated mainly by ACTH and potassium levels,
provided that the renin–angiotensin–aldosterone
system was suppressed.
19–24 The diurnal rhythm of
PAC in patients with an APAwas reported to depend
on that of endogenous ACTH
25–28 and became
ambiguous when the endogenous secretion of ACTH
was disturbed by supraphysiological doses of dex-
amethasone.
21,26,28 Besides, the absolute levels of
PAC decreased when the ACTH levels were sup-
pressed by exogenous glucocorticoids.
21,26,28 Our
patient was complicated by ACTH-independent
Cushing syndrome with totally suppressed levels
of endogenous ACTH, suggesting that her levels of
PAC might have been higher than the physiological
levels. Although her plasma aldosterone levels
showed no obvious diurnal rhythm fluctuation, they
were mostly higher than 12ng per 100ml, and the
ARR was consistently higher than 40, fulfilling the
screening criteria.
2 After the first ADX, the second
circadian study of hypothalamo–pituitary–adrenal
axis and renin–angiotensin–aldosterone system re-
vealed a mean aldosterone level of 11.45ng per
100ml without the apparent diurnal variation
observed when PRA is consistently o1ngml
–1h
 1.
This decrement in PAC might be partly attributable
to the resection of the right microAPA, and we
considered that the high ARR (420) after the first
surgery suggested persistent aldosterone excess.
The second step in the evaluation of hypersecre-
tion of aldosterone lies in confirmatory tests. In our
patient, the volume-overloaded state was evident at
the initial visit and we chose a captopril test. The
results of this test before and after the first ADX were
ARR of 20.8 and 19.6, respectively. Although the
second ARR was slightly below the cut-off level of
20 probably because of a decrease in the aldosterone
level, implying that the aldosterone excess was
partly dependent on angiotensin II, we considered
that both results were high enough to interpret that
somewhat autonomous secretion of aldosterone
might exist considering the suppression of ACTH
secretion.
As another confirmatory test, we performed the
rapid ACTH test to consolidate our assumption that
aldosterone excess might be involved. Some re-
search groups have advocated that an APA produces
an exaggerated increase in aldosterone in response
to exogenous ACTH stimulation
19,20,22–24 and that
this finding is helpful to differentiate patients with
PA from those with low-renin essential hyperten-
sion. Indeed, expression of the melanocortin recep-
tor type 2 in APA is significantly elevated compared
with normal adrenal tissue
29–32 and other adreno-
cortical tumours, including cortisol-producing
ones.
33–35 Therefore, the exaggerated response of
aldosterone through melanocortin receptor type 2
detected with the rapid ACTH test is useful to
distinguish APAs from other cortical tumours.
32,35
Accordingly, we adopted the rapid ACTH test as
another confirmatory test. Stimulation with 0.25mg
cosyntropin elicited peak aldosterone levels as high
as 67.1 and 54.4ng per 100ml before and after the
first ADX, respectively, strongly suggesting the
concomitant excess of aldosterone.
After the confirmation of autonomous excessive
secretion of aldosterone, AVS was performed to
decide the laterality of aldosterone hypersecretion.
2
As for the interpretation of the AVS results, while
many research groups have advocated their methods
and cut-off values,
2 this case may provide valuable
opportunity for interpretation of AVS in patients
with concomitant ACTH-independent Cushing syn-
drome. In patients with autonomous secretion of
cortisol, it would be inappropriate to decide later-
ality of aldosterone hypersecretion based on corti-
sol-corrected aldosterone levels. The cut-off levels of
aldosterone hypersecretion were reported to be 1340
and 1400ng per 100ml by two research groups,
including ours.
3–5 In this case, levels of aldosterone
after cosyntropin stimulation exceeded 1400ng per
100ml bilaterally, indicating that bilateral aldoste-
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quently confirmed by the presence of bilateral
microAPAs. In addition, the AVS showed the higher
aldosterone level in the left adrenal vein than that in
the right after cosyntropin stimulation, in contrast to
the comparable levels of both adrenals at baseline.
This might be partly attributed to possible difference
in capacity of the aldosterone-producing microAPAs
to secrete aldosterone in response to cosyntropin.
The ‘re-advent’ of AVS for clinical practice has
been associated with an increasing number of
reports on CT-undetectable microAPAs in patients
with primary aldosteronism.
36–39 The diagnosis of
microAPA, in our view, should be histopathologi-
cally confirmed in two ways; a micronodule should
be detected by HE staining, and subsequently
immunohistochemically examined for expression
of steroidogenic enzymes.
8,40 The requisite for
diagnosis of a microAPA should include increased
expression of 3b-HSD and attenuated or negative
expression of P450c17 within the lesion, which can
be further supported by the presence of ‘paradoxical
hyperplasia’, that is, suppressed or negative expres-
sion of 3b-HSD in the zona glomerulosa of the
attached adrenal tissue.
8 All the micronodules
diagnosed as microAPAs in this case satisfied these
two conditions.
Furthermore, the cortisol might have a role in the
pathogenesis of severe hypertension in this case.
The autonomous and excessive secretion of cortisol
caused sodium and volume retention, resulting
in pitting oedema, which is not typically observed
in patients with primary aldosteronism. After the
first ADX, Cushing syndrome was remitted and
signs of volume-overloaded state disappeared, while
the hypertension persisted with the aldosterone
levels almost unchanged, suggesting that the cortisol
might be a deteriorating factor to cause excessive
sodium reabsorption under the circumstances that
the excessive aldosterone might have a pivotal role
to keep blood pressure still elevated.
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